Kasabach-Merritt syndrome is a rare and potentially life-threatening condition characterized by the presence of a vascular tumor, known as a hemangioma, along with severe thrombocytopenia and consumption coagulopathy. This syndrome primarily affects infants and young children, although it can occur in individuals of any age.
The term Kasabach-Merritt syndrome is often used interchangeably with other names such as hemangioma thrombocytopenia syndrome or thrombocytopenic coagulopathy with hemangioma. These synonyms reflect the key features of the condition, namely the presence of a hemangioma, low platelet count (thrombocytopenia), and abnormal blood clotting (coagulopathy).
Hemangioma thrombocytopenia syndrome highlights the association between the vascular tumor and low platelet levels. Hemangiomas are abnormal growths of blood vessels that can occur anywhere in the body, but are most commonly found on the skin or internal organs. In Kasabach-Merritt syndrome, the hemangioma leads to platelet trapping and destruction, resulting in thrombocytopenia.
Thrombocytopenic coagulopathy with hemangioma emphasizes the additional complication of abnormal blood clotting. The presence of the hemangioma triggers the release of clotting factors, leading to the formation of blood clots within the tumor. This consumption of clotting factors can result in a coagulopathy, causing excessive bleeding or clotting problems.
It is important to note that while these terms are used synonymously, they all refer to the same underlying condition. The primary focus remains on the combination of a vascular tumor, low platelet count, and abnormal blood clotting. Early recognition and appropriate management of Kasabach-Merritt syndrome are crucial to prevent complications and improve outcomes for affected individuals.